Skip to main content
SpringerLink
Log in

What Does the Future Hold for the Therapy of COPD?

  • Chapter
  • First Online:
Indacaterol

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

Current therapies for COPD fail to prevent disease progression or mortality. The mainstay of current drug therapy is long-acting bronchodilators; several longer-acting inhaled β2-agonists and muscarinic antagonists (and combinations) are now in development. No treatments have so far been shown to suppress chronic inflammation in COPD lungs. With better understanding of the inflammatory and destructive process in the pathophysiology of COPD, several new therapeutic targets have been identified. Several mediator antagonists tested in COPD have so far been disappointing, but CXCR2 antagonists that block pulmonary neutrophil and monocyte recruitment may be more promising. Broad-spectrum anti-inflammatory drugs may be more effective and include inhibitors of the enzymes phosphodiesterase-4, p38 mitogen-activated protein kinase, NF-κB kinase and PI3 kinase-γ and PI3 kinase-δ, but side effects will be a major limitation with systemic administration, so that inhaled delivery may be necessary. Perhaps the most promising approach is reversal of corticosteroid resistance through increasing histone deacetylase-2 (HDAC2) activity. This might be achieved by theophylline-like drugs, selective PI3 kinase-δ inhibitors, more effective antioxidants and nonantibiotic macrolides.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Barnes PJ, Shapiro SD, Pauwels RA (2003) Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22:672–88

    Article  PubMed  CAS  Google Scholar 

  2. Barnes PJ (2008) Emerging pharmacotherapies for COPD. Chest 134:1278–86

    Article  PubMed  CAS  Google Scholar 

  3. Barnes PJ (2008) Future treatments for COPD and its comorbidities. Proc Am Thorac Soc 5:857–64

    Article  PubMed  CAS  Google Scholar 

  4. Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33:1165–85

    Article  PubMed  CAS  Google Scholar 

  5. Barnes PJ (2006) Theophylline for COPD. Thorax 61:742–3

    Article  PubMed  CAS  Google Scholar 

  6. Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183–92

    Article  PubMed  CAS  Google Scholar 

  7. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, Onodera Y, Hizawa N, Nishimura M (2007) Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 62:932–7

    Article  PubMed  Google Scholar 

  8. Sturton G, Persson C, Barnes PJ (2008) Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol Sci 29:340–5

    Article  PubMed  CAS  Google Scholar 

  9. Stevenson CS, Birrell MA (2010) Moving towards a new generation of animal models for asthma and COPD with improved clinical relevance. Pharmacol Ther 130(2):93–105

    Article  PubMed  Google Scholar 

  10. Cazzola M, Macnee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP et al (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31:416–69

    Article  PubMed  CAS  Google Scholar 

  11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–89

    Article  PubMed  CAS  Google Scholar 

  12. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M (2006) Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174:6–14

    Article  PubMed  CAS  Google Scholar 

  13. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2007) Global strategy for the diagnosis, management, and prevention of COPD—2006 update. Am J Respir Crit Care Med 176:532–55

    Article  PubMed  Google Scholar 

  14. Cazzola M, Matera MG (2009) Emerging inhaled bronchodilators: an update. Eur Respir J 34:757–69

    Article  PubMed  CAS  Google Scholar 

  15. Sturton RG, Nicholson AG, Trifilieff A, Barnes PJ (2008) Pharmacological characterization of indacaterol, a novel once daily inhaled 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices. J Pharmacol Exp Ther 324:270–5

    Article  PubMed  CAS  Google Scholar 

  16. Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D’Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M (2008) A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 102:1033–44

    Article  PubMed  Google Scholar 

  17. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B (2010) Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 182:155–62

    Article  PubMed  CAS  Google Scholar 

  18. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, Barnes PJ (2005) Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 128:1974–9

    Article  PubMed  CAS  Google Scholar 

  19. Cazzola M (2009) Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs 10:482–90

    PubMed  CAS  Google Scholar 

  20. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T (2010) QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65:1086–91

    Article  PubMed  Google Scholar 

  21. Ray NC, Alcaraz L (2009) Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review. Expert Opin Ther Pat 19:1–12

    Article  PubMed  CAS  Google Scholar 

  22. Barnes PJ (2004) Mediators of chronic obstructive pulmonary disease. Pharm Rev 56:515–48

    Article  PubMed  CAS  Google Scholar 

  23. Barnes PJ (2008) Cytokine networks in asthma and chronic obstructive pulmonary disease. J Clin Invest 118:3546–56

    Article  PubMed  CAS  Google Scholar 

  24. Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr (2007) Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 16:1909–20

    Article  PubMed  CAS  Google Scholar 

  25. Rennard SI, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, Korenblat P, Smith W, Kaye M, Mandel M, Andrews C, Prabhu R, Donohoue JF, Watt R, Hung KL, Schlenker-Herceg R et al (2007) The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:926–34

    Article  PubMed  CAS  Google Scholar 

  26. Barnes PJ (2007) Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:866–7

    Article  PubMed  Google Scholar 

  27. Paul-Pletzer K (2006) Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. Drugs Today (Barc) 42:559–76

    Article  CAS  Google Scholar 

  28. Donnelly LE, Barnes PJ (2006) Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 27:546–53

    Article  PubMed  CAS  Google Scholar 

  29. Mahler DA, Huang S, Tabrizi M, Bell GM (2004) Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126:926–34

    Article  PubMed  CAS  Google Scholar 

  30. Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H (2010) SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 35:564–70

    Article  PubMed  CAS  Google Scholar 

  31. Costa C, Rufino R, Traves SL, Lapa E, Silva JR, Barnes PJ, Donnelly LE (2008) CXCR3 and CCR5 chemokines in the induced sputum from patients with COPD. Chest 133:26–33

    Article  PubMed  CAS  Google Scholar 

  32. Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL (2008) Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 10:333–42

    Article  PubMed  CAS  Google Scholar 

  33. Wang IM, Stepaniants S, Boie Y, Mortimer JR, Kennedy B, Elliott M, Hayashi S, Loy L, Coulter S, Cervino S, Harris J, Thornton M, Raubertas R, Roberts C, Hogg JC, Crackower M, O’Neill G, Pare PD (2008) Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 177:402–11

    Article  PubMed  CAS  Google Scholar 

  34. Leung SY, Niimi A, Noble A, Oates T, Williams AS, Medicherla S, Protter AA, Chung KF (2006) Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling. J Pharmacol Exp Ther 319:586–94

    Article  PubMed  CAS  Google Scholar 

  35. Groutas WC, Dou D, Alliston KR (2011) Neutrophil elastase inhibitors. Expert Opin Ther Pat 21:339–54

    Article  PubMed  CAS  Google Scholar 

  36. Hu J, Van Den Steen PE, Sang QX, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480–98

    Article  PubMed  CAS  Google Scholar 

  37. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL (2007) Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 62:706–13

    Article  PubMed  Google Scholar 

  38. Li W, Li J, Wu Y, Wu J, Hotchandani R, Cunningham K, McFadyen I, Bard J, Morgan P, Schlerman F, Xu X, Tam S, Goldman SJ, Williams C, Sypek J, Mansour TS (2009) A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b, d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408). J Med Chem 52:1799–802

    Article  PubMed  Google Scholar 

  39. Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 342:1905–17

    Article  Google Scholar 

  40. Suissa S, Barnes PJ (2009) Inhaled corticosteroids in COPD: the case against. Eur Respir J 34:13–6

    Article  PubMed  CAS  Google Scholar 

  41. Giembycz MA (2008) Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 155:288–90

    Article  PubMed  CAS  Google Scholar 

  42. Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172:848–53

    Article  PubMed  Google Scholar 

  43. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H (2010) The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235–56

    Article  PubMed  CAS  Google Scholar 

  44. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF (2007) Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62:1081–7

    Article  PubMed  Google Scholar 

  45. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM (2007) Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176:154–61

    Article  PubMed  CAS  Google Scholar 

  46. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685–94

    Article  PubMed  CAS  Google Scholar 

  47. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374:695–703

    Article  PubMed  CAS  Google Scholar 

  48. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA (2004) Discovery of BRL 50481, a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages and CD8+ T-lymphocytes. Mol Pharmacol 66:1679–89

    Article  PubMed  CAS  Google Scholar 

  49. Giembycz MA (2005) Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:326–33

    Article  PubMed  CAS  Google Scholar 

  50. Banner KH, Press NJ (2009) Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 157:892–906

    Article  PubMed  CAS  Google Scholar 

  51. Birrell MA, Wong S, Hardaker EL, Catley MC, McCluskie K, Collins M, Haj-Yahia S, Belvisi MG (2006) IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 69:1791–800

    Article  PubMed  CAS  Google Scholar 

  52. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, Zuin R, Marsico SA, Saetta M (2008) Increased activation of p38 MAPK in COPD. Eur Respir J 31:62–9

    Article  PubMed  CAS  Google Scholar 

  53. Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MA, Barnes PJ, Donnelly LE (2006) Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br J Pharmacol 149:393–404

    Article  PubMed  CAS  Google Scholar 

  54. Medicherla S, Fitzgerald M, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS (2007) p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 324:921–9

    Article  PubMed  Google Scholar 

  55. Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes PJ, Donnelly LE (2008) Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 324:306–12

    Article  PubMed  CAS  Google Scholar 

  56. Medina-Tato DA, Ward SG, Watson ML (2007) Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond. Immunology 121:448–61

    Article  PubMed  CAS  Google Scholar 

  57. Ameriks MK, Venable JD (2009) Small molecule inhibitors of phosphoinositide 3-kinase (PI3K) delta and gamma. Curr Top Med Chem 9:738–53

    Article  PubMed  CAS  Google Scholar 

  58. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliot M, Hogg JC, Adcock IM, Barnes PJ (2010) Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182:897–904

    Article  PubMed  CAS  Google Scholar 

  59. Marwick JA, Caramori G, Stevenson CC, Casolari P, Jazrawi E, Barnes PJ, Ito K, Adcock IM, Kirkham PA, Papi A (2009) Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 179:542–8

    Article  PubMed  CAS  Google Scholar 

  60. Belvisi MG, Hele DJ, Birrell MA (2006) Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 533:101–9

    Article  PubMed  CAS  Google Scholar 

  61. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ, Reddy RC (2008) PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294:L891–901

    Article  PubMed  CAS  Google Scholar 

  62. Remels AH, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker HR, Schols AM (2007) Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur Respir J 30:245–52

    Article  PubMed  CAS  Google Scholar 

  63. Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ (2007) Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 7, CD002991

    Google Scholar 

  64. Suissa S, Ernst P, Vandemheen KL, Aaron SD (2008) Methodological issues in therapeutic trials of COPD. Eur Respir J 31:927–33

    Article  PubMed  CAS  Google Scholar 

  65. Barnes PJ (2010) Inhaled corticosteroids in COPD: a controversy. Respiration 80:89–95

    Article  PubMed  CAS  Google Scholar 

  66. Barnes PJ (2009) Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71:451–64

    Article  PubMed  CAS  Google Scholar 

  67. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 203:7–13

    Article  PubMed  CAS  Google Scholar 

  68. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–95

    Article  PubMed  CAS  Google Scholar 

  69. Fox JC, Spicer D, Ito K, Barnes PJ, Fitzgerald MF (2007) Oral or inhaled corticosteroid combination therapy with low dose theophylline reverses corticosteroid insensitivity in a smoking mouse model. Proc Am Thorac Soc 2:A637

    Google Scholar 

  70. Ford PA, Durham AL, Russell REK, Gordon F, Adcock IM, Barnes PJ (2010) Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD. Chest 137:1338–44

    Article  PubMed  CAS  Google Scholar 

  71. Kirkham P, Rahman I (2006) Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 111:476–94

    Article  PubMed  CAS  Google Scholar 

  72. Sussan TE, Rangasamy T, Blake DJ, Malhotra D, El Haddad H, Bedja D, Yates MS, Kombairaju P, Yamamoto M, Liby KT, Sporn MB, Gabrielson KL, Champion HC, Tuder RM, Kensler TW, Biswal S (2009) Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc Natl Acad Sci USA 106:250–5

    Article  PubMed  CAS  Google Scholar 

  73. Charron C, Sumakuza T, Oomura S, Ito K (2007) EM-703, a non-antibacterial erythromycin derivative, restores HDAC2 activation diminished by hypoxia and oxidative stress. Proc Am Thorac Soc 175:A640

    Google Scholar 

  74. Stinchcombe SV, Maden M (2008) Retinoic acid-induced alveolar regeneration: critical differences in strain sensitivity. Am J Respir Cell Mol Biol 38:185–91

    Article  PubMed  CAS  Google Scholar 

  75. Roth MD, Connett JE, D’Armiento JM, Foronjy RF, Friedman PJ, Goldin JG, Louis TA, Mao JT, Muindi JR, O’Connor GT, Ramsdell JW, Ries AL, Scharf SM, Schluger NW, Sciurba FC, Skeans MA, Walter RE, Wendt CH, Wise RA (2006) Feasibility of retinoids for the treatment of emphysema study. Chest 130:1334–45

    Article  PubMed  CAS  Google Scholar 

  76. Varanou A, Page CP, Minger SL (2008) Human embryonic stem cells and lung regeneration. Br J Pharmacol 155:316–25

    Article  PubMed  CAS  Google Scholar 

  77. Loebinger MR, Janes SM (2007) Stem cells for lung disease. Chest 132:279–85

    Article  PubMed  Google Scholar 

  78. Ott HC, Clippinger B, Conrad C, Schuetz C, Pomerantseva I, Ikonomou L, Kotton D, Vacanti JP (2010) Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 16:927–33

    Article  PubMed  CAS  Google Scholar 

  79. Salvi SS, Barnes PJ (2009) Chronic obstructive pulmonary disease in non-smokers. Lancet 374:733–43

    Article  PubMed  Google Scholar 

  80. Stolk J, Versteegh MI, Montenij LJ, Bakker ME, Grebski E, Tutic M, Wildermuth S, Weder W, el Bardiji M, Reiber JH, Rabe KF, Russi EW, Stoel BC (2007) Densitometry for assessment of effect of lung volume reduction surgery for emphysema. Eur Respir J 29:1138–43

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse Street, London, SW3 6LY, UK

    Peter J. Barnes

Authors
  1. Peter J. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter J. Barnes .

Editor information

Editors and Affiliations

  1. Respiratory Diseases Area, Novartis Institutes for BioMedical Reseach, Basel, Switzerland

    Alexandre Trifilieff

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Basel

About this chapter

Cite this chapter

Barnes, P.J. (2014). What Does the Future Hold for the Therapy of COPD?. In: Trifilieff, A. (eds) Indacaterol. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0709-8_9

Download citation

Publish with us

Policies and ethics

Search

Navigation